Sasikanth Adigopula, MD
Advanced Heart Failure and Transplant Cardiology · Indianapolis, INNPI 1053325050
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,400 of the $310,239 with a category attached, or 86.5%. 24 manufacturers reported payments, led by Boehringer Ingelheim at 42.0% of the total. 2025 is the largest year on record at $118,352, more than ten times the $372 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $1007.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$130K
- Actelion Pharmaceuticals US, Inc.$54K
- AstraZeneca$42K
- United Therapeutics Corporation$41K
- Lilly USA, LLC$21K
- Abbott$11K
- plus $9K from 18 others
Across 186 payments — averaging $4797.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$450K
- Boston Scientific$383K
- Abbott$37K
- CSL Behring$22K
What the payments were for
- Consulting fees$12,0384%
- Speaking & faculty fees$268,40087%
- Travel & lodging$21,3877%
- Food & beverage$8,2303%
- Education$1840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 73 | $130,352 |
| Actelion Pharmaceuticals US, Inc. | 74 | $54,165 |
| AstraZeneca | 41 | $42,414 |
| United Therapeutics Corporation | 29 | $41,243 |
| Lilly USA, LLC | 16 | $21,185 |
| Abbott | 27 | $11,468 |
| Scpharmaceuticals Inc. | 5 | $7,850 |
| Boston Scientific | 6 | $327 |
| Cvrx, Inc. | 6 | $186 |
| Novo Nordisk | 3 | $152 |
| Merck | 6 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $130 |
| Sanofi-aventis U.S. LLC | 1 | $109 |
| Abiomed | 1 | $100 |
| Livanova USA, Inc. | 1 | $91 |
| Novartis | 4 | $71 |
| Amgen | 3 | $71 |
| Pfizer | 3 | $47 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| Bayer | 2 | $31 |
| Atricure, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$150,823
- OPSUMIT$52,691
- UPTRAVI$48,440
- FARXIGA$33,979
- LOKELMA$7,993
- FUROSCIX$7,850
- MitraClip$4,160
- CardioMEMS HF System$3,400
- HeartMate 3 Left Ventricular Dev$3,188
- TYVASO$1,965
- CARDIOMEMS$284
- CAMZYOS$130
- Barostim Neo System$122
- WAINUA$121
- WATCHMAN FLX$111
- Wegovy$110
- DISEASE STATE$109
How this compares
$310,239 in reported general payments places this provider in the 95th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
See all advanced heart failure and transplant cardiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 12 | $279,740 |
| VyndamaxTafamidis | 11 | $237,705 |
| OpsumitMacitentan | 13 | $160,512 |
| CamzyosMavacamten | 20 | $159,017 |
| JardianceEmpagliflozin | 114 | $96,073 |
| EntrestoSacubitril/Valsartan | 78 | $79,804 |
| FarxigaDapagliflozin Propanediol | 41 | $44,521 |
| Orenitram ErTreprostinil Diolamine | 12 | $42,543 |
| EliquisApixaban | 17 | $16,789 |
| CorlanorIvabradine Hcl | 15 | $12,310 |
| Tadalafil | 19 | $1,502 |
| Torsemide | 53 | $934 |
| Metoprolol Succinate | 37 | $553 |
| Potassium Chloride | 12 | $287 |
| Spironolactone | 45 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $54,165 | $440,25225 claims |
| PfizerVyndamax, Eliquis | $47 | $254,49428 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $130 | $159,01720 claims |
| Boehringer IngelheimJardiance | $130,352 | $96,073114 claims |
| NovartisEntresto | $71 | $79,80478 claims |
| AstraZenecaFarxiga | $42,414 | $44,52141 claims |
| AmgenCorlanor | $71 | $12,31015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
Other advanced heart failure and transplant cardiology in Indianapolis
- Ashwin RavichandranIndianapolis$284K
- Rafael Garcia-CortesIndianapolis$101K
- Amit PatelIndianapolis$41K
- Sunit-Preet ChaudhryIndianapolis$27K
- Radha KannegantiIndianapolis$18K
- Mary WalshIndianapolis$17K
- Bhavana Siddegowda-BangaloreIndianapolis$5K
- Sangita SudharshanIndianapolis$2K
- Muhamad SafiiaIndianapolis$2K
- Philip KirlinIndianapolis$967
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.